Frédéric Dumais
Investor Relations Contact chez VALEO PHARMA INC.
Profil
Frédéric Dumais is currently the Director of Communications & Investor Relations at ChitogenX, Inc., Director of Communications & Investor Relations at Valeo Pharma, Inc., and a Member of the Québec Bar Association.
In the past, he held positions as Director of Communications & Investor Relations at Liminal BioSciences, Inc., Vice President of Investor Relations at LAB International, Inc. and Akela Pharma, Inc., and Head of Investor Relations at Janssen Pharmaceutica NV.
Postes actifs de Frédéric Dumais
| Sociétés | Poste | Début |
|---|---|---|
| VALEO PHARMA INC. | Investor Relations Contact | 01/06/2019 |
| CHITOGENX INC. | Investor Relations Contact | 01/06/2019 |
Québec Bar Assoication
 Québec Bar Assoication Financial ConglomeratesFinance The Québec Bar Association is a professional organization that oversees the practice of over 29,000 lawyers in all areas of law. The organization is based in Montréal, Canada. and has subsidiaries in Canada. The mission of the association is to ensure the protection of the public, contribute to accessible and quality justice, and defend the rule of law. | Corporate Officer/Principal | - |
Anciens postes connus de Frédéric Dumais
| Sociétés | Poste | Fin |
|---|---|---|
LAB International, Inc.
 LAB International, Inc. Pharmaceuticals: MajorHealth Technology LAB International (LAB Pharma and LAB Research) is an integrated drug development company. LAB Pharma is focused on the growing multi-billion dollar inhalation market. Its lead product, for the treatment of breakthrough cancer pain, is a fast-acting Fentanyl formulation delivered using the Company's TAIFUN(R) dry powder inhaler platform. Its pipeline also includes therapeutics for asthma, COPD, and growth hormone deficiencies | Public Communications Contact | 13/07/2007 |
| LIMINAL BIOSCIENCES INC. | Investor Relations Contact | - |
Janssen Pharmaceutica NV
 Janssen Pharmaceutica NV Pharmaceuticals: MajorHealth Technology Janssen Pharmaceutica NV engages in the development of medical solutions. It offers research and development services in the field of mental illness, neurological disorders, anesthesia, analgesia, gastrointestinal disorders, fungal infection, allergies and cancer. The firms products include Zytiga, Caelyx, Dacogen, Edurant, Fentanyl-Janssen, Intelence, Leustatin, , Pariet, and Reminyl. The company was founded in 1953 by Paul Janssen and is headquartered in Beerse, Belgium. | Investor Relations Contact | - |
Akela Pharma, Inc.
 Akela Pharma, Inc. Pharmaceuticals: MajorHealth Technology Akela Pharma, Inc. operates as a drug development company, which develops and manufactures pharmaceutical formulations and drugs. The company operates as a specialty contract pharmaceutical formulation developer and clinical and commercial drug manufacturer for proprietary drug products through its wholly-owned subsidiary, PharmaForm LLC, a pharmaceutical intellectual property development company. It provides specialty contract services in the area of pharmaceutical dosage form development, preclinical, scale-up, clinical and commercial supply manufacturing, focusing on controlled release and bioavailability enhancement technologies, such as hot melt extrusion, spray drying and liquid filled capsules. Akela Pharma was founded on November 15, 1988 and is headquartered in Austin, TX. | Public Communications Contact | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| LIMINAL BIOSCIENCES INC. | Health Technology |
| VALEO PHARMA INC. | Health Technology |
| CHITOGENX INC. | Health Technology |
| Entreprise privées | 4 |
|---|---|
LAB International, Inc.
LAB International, Inc. Pharmaceuticals: MajorHealth Technology LAB International (LAB Pharma and LAB Research) is an integrated drug development company. LAB Pharma is focused on the growing multi-billion dollar inhalation market. Its lead product, for the treatment of breakthrough cancer pain, is a fast-acting Fentanyl formulation delivered using the Company's TAIFUN(R) dry powder inhaler platform. Its pipeline also includes therapeutics for asthma, COPD, and growth hormone deficiencies | Health Technology |
Akela Pharma, Inc.
Akela Pharma, Inc. Pharmaceuticals: MajorHealth Technology Akela Pharma, Inc. operates as a drug development company, which develops and manufactures pharmaceutical formulations and drugs. The company operates as a specialty contract pharmaceutical formulation developer and clinical and commercial drug manufacturer for proprietary drug products through its wholly-owned subsidiary, PharmaForm LLC, a pharmaceutical intellectual property development company. It provides specialty contract services in the area of pharmaceutical dosage form development, preclinical, scale-up, clinical and commercial supply manufacturing, focusing on controlled release and bioavailability enhancement technologies, such as hot melt extrusion, spray drying and liquid filled capsules. Akela Pharma was founded on November 15, 1988 and is headquartered in Austin, TX. | Health Technology |
Québec Bar Assoication
Québec Bar Assoication Financial ConglomeratesFinance The Québec Bar Association is a professional organization that oversees the practice of over 29,000 lawyers in all areas of law. The organization is based in Montréal, Canada. and has subsidiaries in Canada. The mission of the association is to ensure the protection of the public, contribute to accessible and quality justice, and defend the rule of law. | Finance |
Janssen Pharmaceutica NV
Janssen Pharmaceutica NV Pharmaceuticals: MajorHealth Technology Janssen Pharmaceutica NV engages in the development of medical solutions. It offers research and development services in the field of mental illness, neurological disorders, anesthesia, analgesia, gastrointestinal disorders, fungal infection, allergies and cancer. The firms products include Zytiga, Caelyx, Dacogen, Edurant, Fentanyl-Janssen, Intelence, Leustatin, , Pariet, and Reminyl. The company was founded in 1953 by Paul Janssen and is headquartered in Beerse, Belgium. | Health Technology |
